Sertraline myopathy
Evidence-based neurology checklist on sertraline myopathy: Pathology Sertraline produces a lipid storage myopathy It inhibits mitochondrial electron transport chain (ETC) complexes at complex I, II and IV It results in acquired multiple acyl-CoA dehydrogenase deficiency (MADD) Clinical features…
Pathology
- Sertraline produces a lipid storage myopathy
- It inhibits mitochondrial electron transport chain (ETC) complexes at complex I, II and IV
- It results in acquired multiple acyl-CoA dehydrogenase deficiency (MADD)
Clinical features
Investigations
Treatment
References
- Shaibani A, Taylor A. Sertraline-associated riboflavin-responsive lipid storage myopathy: report of two case. Muscle Nerve 2026; 73:309-312.
- Hedberg-Oldfors C, Lindgren U, Visuttijai K, et al. Lipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency. Acta Neuropathol 2024; 148:73.
- Sunebo S, Nilsson E, Engvall M, et al. Acquired multiple acyl-coenzyme a dehydrogenase deficiency associated with sertraline in Sweden-a nationwide population-based study. Eur J Neurol 2026; 33:e70555.
- Valerius AR, Wannarong T, Rael S, et al. Very-late onset multiple acyl-coenzyme a dehydrogenase deficiency associated with sertraline use: a case report. J Clin Neuromuscul Dis 2025; 27:14-17.
- Sunebo S, Appelqvist H, Häggqvist B, Danielsson O. Multiple acyl-coenzyme a dehydrogenase deficiency is associated with sertraline use - is there an acquired form? Ann Neurol 2024; 96:802-811.
- And 0 more. Subscribe to see the full list
